Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1752166 | 0.79 | GPR3 (0.32) | GPR3SMN1; SMN2KDM4ENPC1ALDH1A1 | |
| SCHEMBL5511626 | 0.78 | GRM2 (0.32) | — | |
| SCHEMBL30776600 | 0.78 | GRM2 (0.32) | — | |
| SCHEMBL29957339 | 0.77 | MAPT (0.32) | GPR3SMN1; SMN2KDM4ENPC1ALDH1A1 | |
| SCHEMBL3450325 | 0.77 | MAPT (0.32) | GPR3SMN1; SMN2KDM4ENPC1ALDH1A1 | |
| SCHEMBL3450328 | 0.74 | KDM4E (0.31) | KDM4EALDH1A1HPGD | |
| SCHEMBL29830999 | 0.74 | GPR3 (0.33) | GPR3SMN1; SMN2HPGDHTR6GPR84 | |
| SCHEMBL1077030 | 0.74 | GPR3 (0.33) | GPR3SMN1; SMN2HPGDHTR6GPR84 | |
| SCHEMBL29957737 | 0.71 | ALDH1A1 (0.33) | ALDH1A1IMPDH2 | |
| SCHEMBL5016700 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| CN-101460461-B | Process for preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carboxylic acids | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | disclosed |
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | BACHMANN STEPHAN | 2011-05-05 | — | — | US | disclosed |
| EP-2029541-B1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2009-12-30 | — | — | EP | disclosed |
| CN-101460461-A | Process for preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carboxylic acids | HOFFMANN LA ROCHE (CH) | 2009-06-17 | — | — | CN | disclosed |
| CN-100408575-C | Aryl-8-azabicyclo[3,2,1]octanes for treating depression | WYETH CORP (US) | 2008-08-06 | — | — | CN | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| US-7060830-B2 | Synthesized γ-carbolines | GEORGE MASON INTELLECTUAL PROPERTIES, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050176759-A1 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20050131010-A1 | Synthesized gamma-carbolines | WYNNE JAMES H (US) | 2005-06-16 | — | — | US | disclosed |
| US-6872830-B1 | Synthesized γ-carbolines | GEORGE MASON UNIVERSITY (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1390364-B1 | ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION | WYETH CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| CN-1509287-A | Aryl-8-azabicyclo[3,2,1]octanes for treating depression | — | 2004-06-30 | — | — | CN | disclosed |
| US-6632824-B2 | Have the ability to act at the 5-HT transporter. | WYETH | 2003-10-14 | — | — | US | disclosed |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | WYETH | 2003-02-13 | — | — | US | disclosed |
| EP-1021423-A1 | MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNF$g(a) SECRETION | Abbott Laboratories (US) | 2000-07-26 | — | — | EP | disclosed |
| US-5952320-A | USEFUL IN THE TREATMENT OF DISEASES IN WHICH MATRIX METALLOPROTEINASE PLAY A ROLE; MATRIX METALLOPROTEINASE INHIBITING COMPOSITIONS | ABBOTT LABORATORIES (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1998030551-A1 | MACROCYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES AND TNFα SECRETION | ABBOTT LABORATORIES (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105758-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS | AHR, AR, CYP8B1 | GPR3 1041/4885SMN1; SMN2 4520/4885KDM4E 4079/4885 |
| US-20030032645-A1 | Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression | HTR1A, HTR1D, HTR2C | GPR3 341/4885SMN1; SMN2 3226/4885KDM4E 404/4885 |
| US-20050176759-A1 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders | MPL, HTR2B, PDGFRB | GPR3 206/4885SMN1; SMN2 491/4885KDM4E 2679/4885 |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | AHR, CYP8B1, ADRA2C | GPR3 749/4885SMN1; SMN2 4529/4885KDM4E 4211/4885 |
| US-20050131010-A1 | Synthesized gamma-carbolines | SNCA, PARK7, PRNP | GPR3 948/4885SMN1; SMN2 1121/4885KDM4E 1744/4885 |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | AHR, CYP8B1, ADRA2C | GPR3 749/4885SMN1; SMN2 4529/4885KDM4E 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.